secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2023-11-17T23:59:59+00:00
Accession:  0001104659-23-119532
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics terminates at-the-market offering agreement with Cantor Fitzgerald
--------------------------------------------------------------------------------

- Terminated Controlled Equity Offering Sales Agreement with Cantor Fitzgerald effective Nov 13, 2023.
- Agreement allowed for at-the-market sales; 865,535 shares sold for net proceeds of $3.5M total.
- Company gave immediate notice; no reason for termination provided in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465923119532/0001104659-23-119532-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465923119532/tm2330139d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-119532

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer